Optimal Use of Disease-Modifying Therapies in Transthyretin Amyloid Cardiomyopathy

Jose Nativi Nicolau, MD

March 07, 2023

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a common yet underrecognized form of amyloidosis, a group of diseases characterized by the abnormal buildup of amyloid.

In ATTR-CM, the protein aggregates deposit in the walls of the left ventricle, and until recently there was no specific therapy for this potentially fatal disease.

Jose Nativi Nicolau, MD, a leading cardiologist at the Mayo Clinic in Jacksonville, Florida, explains that the diagnosis of ATTR-CM is often delayed. This is largely due to the constellation of symptoms of this disease, which can appear separately, sometimes over a period of years.

He discusses the diagnostic tools that can be used to establish a diagnosis and sets out the key points of the 2023 multidisciplinary diagnostic algorithm recommended by the American College of Cardiology.

Dr Nativi Nicolau then examines the therapeutic approaches for treating patients with ATTR-CM before looking at the evidence in support of tafamidis, the only FDA-approved drug for the disease.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Optimal Use of Disease-Modifying Therapies in Transthyretin Amyloid Cardiomyopathy - Medscape - Mar 07, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.